Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Venous Thrombosis

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 20 articles:
HTML format



Single Articles


    April 2021
  1. ARCHULETA J, van der Graaf M, Kaptein FHJ, Althaus L, et al
    Sudden death due to massive bone marrow sequestration crisis in a patient with sickle cell disease.
    Am J Hematol. 2021;96:E100-E102.
    PubMed    


    March 2021
  2. WARKENTIN TE, Smythe MA, Ali MA, Aslam N, et al
    Serotonin-release assay-positive but platelet factor 4-dependent enzyme-immunoassay negative: HIT or not HIT?
    Am J Hematol. 2021;96:320-329.
    PubMed     Abstract available


    December 2020
  3. HANFF TC, Mohareb AM, Giri J, Cohen JB, et al
    Thrombosis in COVID-19.
    Am J Hematol. 2020;95:1578-1589.
    PubMed     Abstract available


    August 2020
  4. STEFELY JA, Christensen BB, Gogakos T, Cone Sullivan JK, et al
    Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25979.
    PubMed     Abstract available


    July 2020
  5. GUPTA VK, Strykowski R, Scarpato B, Lawrence R, et al
    The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease.
    Am J Hematol. 2020 Jul 3. doi: 10.1002/ajh.25923.
    PubMed    


    October 2019
  6. CHALAYER E, Teste A, Guyotat D, Elalamy I, et al
    Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: external validation of the IMPEDE VTE score.
    Am J Hematol. 2019 Oct 15. doi: 10.1002/ajh.25658.
    PubMed    


    August 2019
  7. SANFILIPPO KM, Luo S, Wang TF, Fiala M, et al
    Predicting Venous Thromboembolism in Multiple Myeloma: Development and Validation of the IMPEDE VTE Score.
    Am J Hematol. 2019 Aug 4. doi: 10.1002/ajh.25603.
    PubMed     Abstract available


  8. WYSOKINSKI WE, Houghton DE, Casanegra AI, Vlazny DT, et al
    Comparison of Apixaban to Rivaroxaban and Enoxaparin in Acute Cancer-Associated Venous Thromboembolism.
    Am J Hematol. 2019 Aug 4. doi: 10.1002/ajh.25604.
    PubMed     Abstract available


    May 2019
  9. BRUNSON A, Keegan T, Mahajan A, White R, et al
    High Incidence of Venous Thromboembolism Recurrence in Patients with Sickle Cell Disease.
    Am J Hematol. 2019 May 9. doi: 10.1002/ajh.25508.
    PubMed     Abstract available


    March 2019
  10. PEGOURIE B, Karlin L, Benboubker L, Orsini-Piocelle F, et al
    Apixaban for the prevention of thromboembolism in Immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
    Am J Hematol. 2019 Mar 11. doi: 10.1002/ajh.25459.
    PubMed     Abstract available


    September 2018
  11. CHI G, Gibson CM, Liu Y, Hernandez AF, et al
    Inverse Relationship of Serum Albumin to the Risk of Venous Thromboembolism Among Acutely Ill Hospitalized Patients: Analysis from the APEX Trial.
    Am J Hematol. 2018 Sep 25. doi: 10.1002/ajh.25296.
    PubMed     Abstract available


    July 2018
  12. SOGAARD M, Nielsen PB
    Anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution.
    Am J Hematol. 2018 Jul 22. doi: 10.1002/ajh.25164.
    PubMed     Abstract available


    June 2018
  13. STREIFF MB, Milentijevic D, McCrae K, Yannicelli D, et al
    An Answer to "Anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution" by Mette Sogaard and Peter Bronnum Nielsen.
    Am J Hematol. 2018 Jun 15. doi: 10.1002/ajh.25165.
    PubMed    


    May 2018
  14. CHEN YW, Wang MJ, Khorana AA
    Prevalence of Venous Thromboembolism Diagnosed in Emergency Department Visits by Cancer Patients and Associated Healthcare Resource Utilization in the United States.
    Am J Hematol. 2018 May 23. doi: 10.1002/ajh.25148.
    PubMed    


    February 2018
  15. STREIFF MB, Milentijevic D, McCrae K, Yannicelli D, et al
    Effectiveness and Safety of Anticoagulants for the Treatment of Venous Thromboembolism in Patients With Cancer.
    Am J Hematol. 2018 Feb 3. doi: 10.1002/ajh.25059.
    PubMed     Abstract available


    November 2017
  16. ALMAKADI M, Sheasgreen C, Barefah A, Lu L, et al
    The Risk of Venous Thromboembolism in Patients with Clinically Overt Gastrointestinal Bleeding.
    Am J Hematol. 2017 Nov 9. doi: 10.1002/ajh.24967.
    PubMed    


    August 2017
  17. COLTRO G, Mannelli F, Guglielmelli P, Pacilli A, et al
    A life-threatening ruxolitinib discontinuation syndrome.
    Am J Hematol. 2017;92:833-838.
    PubMed    


    March 2017
  18. CHEN YW, Khorana A
    The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the SAVE-ONCO Trial control arm.
    Am J Hematol. 2017 Mar 6. doi: 10.1002/ajh.24712.
    PubMed    


    February 2017
  19. PATELL R, Rybicki L, McCrae KR, Khorana AA, et al
    Predicting Risk Of Venous Thromboembolism In Hospitalized Cancer Patients: Utility of A Risk Assessment Tool.
    Am J Hematol. 2017 Feb 27. doi: 10.1002/ajh.24700.
    PubMed     Abstract available


    January 2017
  20. OVANESOV MV, Menis MD, Scott DE, Forshee R, et al
    Association of Immune Globulin Intravenous (IGIV) and Thromboembolic Adverse Events (TEEs).
    Am J Hematol. 2017 Jan 9. doi: 10.1002/ajh.24644.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Venous Thrombosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: